# A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece

> **NCT02618122** · — · COMPLETED · sponsor: **Genesis Pharma S.A.** · enrollment: 63 (actual)

## Conditions studied

- Advanced Soft Tissue Sarcoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02618122
- **Lead sponsor:** Genesis Pharma S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2019-06-30
- **Final completion:** 2019-08-06
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02618122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02618122, "A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02618122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*